Biography
Prof. Patrick Forde is Prendergast Professor of Immuno-Oncology at Trinity College Dublin and Consultant Medical Oncologist at St. James Hospital Dublin as well as a professor at Johns Hopkins University. He has led the development of immunotherapy for surgically resectable lung cancer from initial concept to worldwide use, initially exploring the role of single agent anti-PD-1 as neoadjuvant therapy and later as principal investigator of the CheckMate 816 trial which led to the approval internationally of neoadjuvant chemo-immunotherapy for stage II-III lung cancer. Long term follow up from this study showed that just 3 doses of immunotherapy before surgery significantly improved long term survival for patients with lung cancer. He leads several translational efforts to optimize the treatment of lung cancer including the global platform neoadjuvant immunotherapy trial, NeoCOAST-2, exploring novel immunotherapy combinations prior to surgery for lung cancer.
Publications and Further Research Outputs
Peer-Reviewed Publications
Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, Meadows-Shropshire S, Fiore J, Bhatia S, Girard N;, Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer, New England Journal of Medicine, 2025
Huang, P., Illei, P.B., Franklin, W., Wu, P.-H., Forde, P.M., Ashrafinia, S., Hu, C., Khan, H., Vadvala, H.V., Shih, I.-M., Battafarano, R.J., Jacobs, M.A., Kong, X., Lewis, J., Yan, R., Chen, Y., Housseau, F., Rahmim, A., Fishman, E.K., Ettinger, D.S., Pienta, K.J., Wirtz, D., Brock, M.V., Lam, S., Gabrielson, E., Lung Cancer Recurrence Risk Prediction through Integrated Deep Learning Evaluation, Cancers, 14, (17), 2022
Friedlaender, A., Naidoo, J., Luigi Banna, G., Metro, G., Forde, P., Addeo, A., Corrigendum to "Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC" [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350)), Cancer Treatment Reviews, 104, 2022
Ricciuti, B., Wang, X., Alessi, J.V., Rizvi, H., Mahadevan, N.R., Li, Y.Y., Polio, A., Lindsay, J., Umeton, R., Sinha, R., Vokes, N.I., Recondo, G., Lamberti, G., Lawrence, M., Vaz, V.R., Leonardi, G.C., Plodkowski, A.J., Gupta, H., Cherniack, A.D., Tolstorukov, M.Y., Sharma, B., Felt, K.D., Gainor, J.F., Ravi, A., Getz, G., Schalper, K.A., Henick, B., Forde, P., Anagnostou, V., Jänne, P.A., Van Allen, E.M., Nishino, M., Sholl, L.M., Christiani, D.C., Lin, X., Rodig, S.J., Hellmann, M.D., Awad, M.M., Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers with Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels, JAMA Oncology, 8, (8), 2022, p1160-1168
Rosner, S., Forde, P.M., Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC, Journal of Thoracic Oncology, 17, (4), 2022, p503-509
Cappelli, L.C., Bingham, C.O., Forde, P.M., Anagnostou, V., Brahmer, J., Lipson, E.J., Mammen, J., Schollenberger, M., Shah, A.A., Darrah, E., Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis, RMD Open, 8, (2), 2022
Valsamo Anagnostou, Blair V. Landon, Jamie E. Medina, Patrick Forde, Victor E. Velculescu, Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy, Science Translational Medicine, 2022
Guo, M.Z., Murray, J.C., Ghanem, P., Voong, K.R., Hales, R.K., Ettinger, D., Lam, V.K., Hann, C.L., Forde, P.M., Brahmer, J.R., Levy, B.P., Feliciano, J.L., Marrone, K.A., Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer, Clinical Lung Cancer, 23, (7), 2022, p620-629
Hsu, M.L., Murray, J.C., Psoter, K.J., Zhang, J., Barasa, D., Brahmer, J.R., Ettinger, D.S., Forde, P.M., Hann, C.L., Lam, V.K., Levy, B., Marrone, K.A., Patel, T., Peterson, V., Sagorsky, S., Turner, M., Anagnostou, V., Naidoo, J., Feliciano, J.L., Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy, Oncologist, 27, (11), 2022, p971-981
Forde, P.M., Spicer, J., Girard, N., Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply, The New England journal of medicine, 387, (6), 2022, p572-573
Schad, S.E., Chow, A., Mangarin, L., Pan, H., Zhang, J., Ceglia, N., Caushi, J.X., Malandro, N., Zappasodi, R., Gigoux, M., Hirschhorn, D., Budhu, S., Amisaki, M., Arniella, M., Redmond, D., Chaft, J., Forde, P.M., Gainor, J.F., Hellmann, M.D., Balachandran, V., Shah, S., Smith, K.N., Pardoll, D., Elemento, O., Wolchok, J.D., Merghoub, T., Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions, Journal of Experimental Medicine, 219, (6), 2022
Shah, P.P., Franke, J.L., Medikonda, R., Jackson, C.M., Srivastava, S., Choi, J., Forde, P.M., Brahmer, J.R., Ettinger, D.S., Feliciano, J.L., Levy, B.P., Marrone, K.A., Naidoo, J., Redmond, K.J., Kleinberg, L.R., Lim, M., Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy, Journal of Neurosurgery, 136, (1), 2022, p56-66
Hong, D.S., Rixe, O., Chiu, V.K., Forde, P.M., Dragovich, T., Lou, Y., Nayak-Kapoor, A., Leidner, R., Atkins, J.N., Collaku, A., Fox, F.E., Marshall, M.A., Olszanski, A.J., Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors, Clinical Cancer Research, 28, (3), 2022, p479-488
Liang, W., Cai, K., Cao, Q., Chen, C., Chen, H., Chen, J., Chen, K.-N., Chen, Q., Chu, T., Dong, Y., Fan, J., Fang, W., Fu, J., Fu, X., Gao, S., Ge, D., Geng, G., Geng, Q., He, J., Hu, J., Hu, J., Hu, W.-D., Jiang, F., Jiang, T., Jiao, W., Li, H.-C., Li, Q., Li, S., Li, S., Li, X., Liao, Y.-D., Liu, C., Liu, H., Liu, Y., Lu, Z., Luo, Q., Ma, H., Pan, X., Qiao, G., Ren, S., Shen, W., Song, Y., Sun, D., Wang, G., Wang, J., Wang, M., Wang, Q., Wang, W.-X., Wei, L., Wu, M., Wu, N., Xia, H., Xu, S.-D., Yang, F., Yang, K., Yang, Y., Yu, F., Yu, Z.-T., Yue, D.-S., Zhang, L., Zhang, W., Zhang, Z., Zhao, G., Zhao, J., Zhao, X., Zhou, C., Zhou, Q., Zhu, K., Zhu, Y., Hida, T., Dempke, W.C.M., Rossi, A., de Perrot, M., Ramirez, R.A., Provencio, M., Lee, J.M., Passaro, A., Spaggiari, L., Spicer, J., Girard, N., Forde, P.M., Mok, T.S.K., Cascone, T., He, J., International expert consensus on immunotherapy for early-stage non-small cell lung cancer, Translational Lung Cancer Research, 11, (9), 2022, p1742-1762
Govindan, R., Aggarwal, C., Antonia, S.J., Davies, M., Dubinett, S.M., Ferris, A., Forde, P.M., Garon, E.B., Goldberg, S.B., Hassan, R., Hellmann, M.D., Hirsch, F.R., Johnson, M.L., Malik, S., Morgensztern, D., Neal, J.W., Patel, J.D., Rimm, D.L., Sagorsky, S., Schwartz, L.H., Sepesi, B., Herbst, R.S., Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma, Journal for ImmunoTherapy of Cancer, 10, (5), 2022
Kok, P.S., Forde, P.M., Hughes, B., Sun, Z., Brown, C., Ramalingam, S., Cook, A., Lesterhuis, W.J., Yip, S., O'Byrne, K., Pavlakis, N., Brahmer, J., Anagnostou, V., Ford, K., Fitzpatrick, K., Bricker, A., Cummins, M.M., Stockler, M., Nowak, A.K., Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial, BMJ Open, 12, (1), 2022
Scott, S.C., Shao, X.M., Niknafs, N., Balan, A., Pereira, G., Marrone, K.A., Lam, V.K., Murray, J.C., Feliciano, J.L., Levy, B.P., Ettinger, D.S., Hann, C.L., Brahmer, J.R., Forde, P.M., Karchin, R., Naidoo, J., Anagnostou, V., Sex-specific differences in immunogenomic features of response to immune checkpoint blockade, Frontiers in Oncology, 12, 2022
Rosner, S., Liu, C., Forde, P.M., Hu, C., Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis, JTO Clinical and Research Reports, 3, (9), 2022
Friedlaender, A., Naidoo, J., Banna, G.L., Metro, G., Forde, P., Addeo, A., Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC, Cancer Treatment Reviews, 104, 2022
Forde, P.M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M.M., Felip, E., Broderick, S.R., Brahmer, J.R., Swanson, S.J., Kerr, K., Wang, C., Ciuleanu, T.-E., Saylors, G.B., Tanaka, F., Ito, H., Chen, K.-N., Liberman, M., Vokes, E.E., Taube, J.M., Dorange, C., Cai, J., Fiore, J., Jarkowski, A., Balli, D., Sausen, M., Pandya, D., Calvet, C.Y., Girard, N., Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer, New England Journal of Medicine, 386, (21), 2022, p1973-1985
Tarhini, A.A., Eads, J.R., Moore, K.N., Tatard-Leitman, V., Wright, J., Forde, P.M., Ferris, R.L., Neoadjuvant immunotherapy of locoregionally advanced solid tumors, Journal for ImmunoTherapy of Cancer, 10, (8), 2022
Liang, K.-L., Tackett, S., Myers, S., Brahmer, J.R., Browner, I.S., Ettinger, D.S., Forde, P.M., Hales, R.K., Hann, C.L., Lam, V.K., Marrone, K.A., Patel, T., Peterson, V., Sagorsky, S., Turner, M., Voong, K.R., Naidoo, J., Feliciano, J.L., An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis, Current Oncology, 29, (6), 2022, p4342-4353
Gerber, D.E., Singh, H., Larkins, E., Ferris, A., Forde, P.M., Selig, W., Basu Roy, U., A New Approach to Simplifying and Harmonizing Cancer Clinical Trials - Standardizing Eligibility Criteria, JAMA Oncology, 8, (9), 2022, p1333-1339
A. S. Mansfield, Z. Wei, R. Mehra, A. T. Shaw, C. H. Lieu, P. M. Forde, A. E. Drilon, E. P. Mitchell, J. J. Wright, N. Takebe, E. Sharon, D. Hovelson, S. Tomlins, J. Zeng, K. Poorman, N. Malik, R. J. Gray, S. Li, L. M. McShane, L. V. Rubinstein, D. Patton, P. M. Williams, S. R. Hamilton, B. A. Conley, C. L. Arteaga, L. N. Harris, P. J. O"Dwyer, A. P. Chen, K. T. Flaherty, Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial, npj Precision Oncology, 2022
Shaikh, F.Y., Gills, J.J., Mohammad, F., White, J.R., Stevens, C.M., Ding, H., Fu, J., Tam, A., Blosser, R.L., Domingue, J.C., Larman, T.C., Chaft, J.E., Spicer, J.D., Reuss, J.E., Naidoo, J., Forde, P.M., Ganguly, S., Housseau, F., Pardoll, D.M., Sears, C.L., Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors, Cancer Immunology, Immunotherapy, 71, (10), 2022, p2405-2420
Gridelli, C., Peters, S., Mok, T., Forde, P.M., Reck, M., Attili, I., de Marinis, F., First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology, ESMO Open, 7, (1), 2022
Chaft, J.E., Shyr, Y., Sepesi, B., Forde, P.M., Preoperative and Postoperative Systemic Therapy for Operable Non"Small-Cell Lung Cancer, Journal of Clinical Oncology, 40, (6), 2022, p546-555
Hwang, M., Canzoniero, J.V., Rosner, S., Zhang, G., White, J.R., Belcaid, Z., Cherry, C., Balan, A., Pereira, G., Curry, A., Niknafs, N., Zhang, J., Smith, K.N., Sivapalan, L., Chaft, J.E., Reuss, J.E., Marrone, K., Murray, J.C., Li, Q.K., Lam, V., Levy, B.P., Hann, C., Velculescu, V.E., Brahmer, J.R., Forde, P.M., Seiwert, T., Anagnostou, V., Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy, Journal for ImmunoTherapy of Cancer, 10, (6), 2022
Mansfield, A.S., Brown, R.J., Sammon, C., Daumont, M.J., McKenna, M., Sanzari, J.K., Forde, P.M., The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review, JTO Clinical and Research Reports, 3, (5), 2022
Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z. Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N. Smith, Archana Balan, James R. White, Christopher Cherry, I. K. Ashok Sivakumar, Xiaoshan M. Shao, Hok Yee Chan, Dipika Singh, Sampriti Thapa, Peter B. Illei, Drew M. Pardoll, Rachel Karchin, Victor E. Velculescu, Julie R. Brahmer, Suresh S. Ramalingam, Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial, Nature Medicine, 27, (11), 2021, p1910--1920
Chen, X., Sheikh, K., Nakajima, E., Lin, C.T., Lee, J., Hu, C., Hales, R.K., Forde, P.M., Naidoo, J., Voong, K.R., Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies, Oncologist, 26, (10), 2021, pe1822-e1832
Reuss, J.E., Brigham, E., Psoter, K.J., Voong, K.R., Shankar, B., Ettinger, D.S., Marrone, K.A., Hann, C.L., Levy, B., Feliciano, J.L., Brahmer, J.R., Feller-Kopman, D., Lerner, A.D., Lee, H., Yarmus, L., Hales, R.K., D'Alessio, F., Danoff, S.K., Forde, P.M., Suresh, K., Naidoo, J., Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC, JTO Clinical and Research Reports, 2, (10), 2021
Curigliano, G., Gelderblom, H., Mach, N., Doi, T., Tai, D., Forde, P.M., Sarantopoulos, J., Bedard, P.L., Lin, C.-C., Stephen Hodi, F., Wilgenhof, S., Santoro, A., Sabatos-Peyton, C.A., Longmire, T.A., Xyrafas, A., Sun, H., Gutzwiller, S., Manenti, L., Naing, A., Phase I/Ib clinical trial of sabatolimab, an anti"TIM-3 antibody, alone and in combination with spartalizumab, an anti"PD-1 antibody, in advanced solid tumors, Clinical Cancer Research, 27, (13), 2021, p3620-3629
Mathios, D., Johansen, J.S., Cristiano, S., Medina, J.E., Phallen, J., Larsen, K.R., Bruhm, D.C., Niknafs, N., Ferreira, L., Adleff, V., Chiao, J.Y., Leal, A., Noe, M., White, J.R., Arun, A.S., Hruban, C., Annapragada, A.V., Jensen, S.Ø., Ørntoft, M.-B.W., Madsen, A.H., Carvalho, B., de Wit, M., Carey, J., Dracopoli, N.C., Maddala, T., Fang, K.C., Hartman, A.-R., Forde, P.M., Anagnostou, V., Brahmer, J.R., Fijneman, R.J.A., Nielsen, H.J., Meijer, G.A., Andersen, C.L., Mellemgaard, A., Bojesen, S.E., Scharpf, R.B., Velculescu, V.E., Detection and characterization of lung cancer using cell-free DNA fragmentomes, Nature Communications, 12, (1), 2021
Friedes, C., Chakrabarti, T., Olson, S., Prichett, L., Brahmer, J.R., Forde, P.J., Voong, R.K., Marrone, K.A., Lam, V.K., Hann, C.L., Broderick, S.R., Battafarano, R.J., Ha, J.S., Bush, E.L., Yang, S.C., Hales, R.K., Feliciano, J.L., Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy, Lung Cancer, 154, 2021, p36-43
Caushi, J.X., Zhang, J., Ji, Z., Vaghasia, A., Zhang, B., Hsiue, E.H.-C., Mog, B.J., Hou, W., Justesen, S., Blosser, R., Tam, A., Anagnostou, V., Cottrell, T.R., Guo, H., Chan, H.Y., Singh, D., Thapa, S., Dykema, A.G., Burman, P., Choudhury, B., Aparicio, L., Cheung, L.S., Lanis, M., Belcaid, Z., El Asmar, M., Illei, P.B., Wang, R., Meyers, J., Schuebel, K., Gupta, A., Skaist, A., Wheelan, S., Naidoo, J., Marrone, K.A., Brock, M., Ha, J., Bush, E.L., Park, B.J., Bott, M., Jones, D.R., Reuss, J.E., Velculescu, V.E., Chaft, J.E., Kinzler, K.W., Zhou, S., Vogelstein, B., Taube, J.M., Hellmann, M.D., Brahmer, J.R., Merghoub, T., Forde, P.M., Yegnasubramanian, S., Ji, H., Pardoll, D.M., Smith, K.N., Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers (Nature, (2021), 596, 7870, (126-132), 10.1038/s41586-021-03752-4), Nature, 598, (7881), 2021, pE1
Balaji, A., Hsu, M., Lin, C.T., Feliciano, J., Marrone, K., Brahmer, J.R., Forde, P.M., Hann, C., Zheng, L., Lee, V., Illei, P.B., Danoff, S.K., Suresh, K., Naidoo, J., Steroid-refractory PD-(L)1 pneumonitis: Incidence, clinical features, treatment, and outcomes, Journal for ImmunoTherapy of Cancer, 9, (1), 2021
Kumar, D., Mishra, A., Lisok, A., Kureshi, R., Shelake, S., Plyku, D., Sen, R., Doucet, M., De Silva, R.A., Mease, R.C., Forde, P.M., Jaffee, E.M., Desai, P., Ganguly, S., Gabrielson, E., Vaidya, D., Spangler, J.B., Nimmagadda, S., Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics, Proceedings of the National Academy of Sciences of the United States of America, 118, (37), 2021
Anagnostou, V., Niknafs, N., Marrone, K., Bruhm, D.C., White, J.R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M., Rosner, S., Reuss, J.E., Smith, K.N., Adleff, V., Rodgers, K., Belcaid, Z., Rhymee, L., Levy, B., Feliciano, J., Hann, C.L., Ettinger, D.S., Georgiades, C., Verde, F., Illei, P., Li, Q.K., Baras, A.S., Gabrielson, E., Brock, M.V., Karchin, R., Pardoll, D.M., Baylin, S.B., Brahmer, J.R., Scharpf, R.B., Forde, P.M., Velculescu, V.E., Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer, Nature cancer, 1, (1), 2020, p99-111
Naidoo, J., Reuss, J.E., Suresh, K., Feller-Kopman, D., Forde, P.M., Mehta Steinke, S., Rock, C., Johnson, D.B., Nishino, M., Brahmer, J.R., Immune-related (IR)-pneumonitis during the COVID-19 pandemic: Multidisciplinary recommendations for diagnosis and management, Journal for ImmunoTherapy of Cancer, 8, (1), 2020
Naing, A., Gainor, J.F., Gelderblom, H., Forde, P.M., Butler, M.O., Lin, C.-C., Sharma, S., Ochoa De Olza, M., Varga, A., Taylor, M., Schellens, J.H.M., Wu, H., Sun, H., Silva, A.P., Faris, J., Mataraza, J., Cameron, S., Bauer, T.M., A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors, Journal for ImmunoTherapy of Cancer, 8, (1), 2020
Linehan, A., Forde, P.M., Moving Immunotherapy into Early-Stage Lung Cancer, Cancer Journal (United States), 26, (6), 2020, p543-547
Shankar, B., Zhang, J., Naqash, A.R., Forde, P.M., Feliciano, J.L., Marrone, K.A., Ettinger, D.S., Hann, C.L., Brahmer, J.R., Ricciuti, B., Owen, D., Toi, Y., Walker, P., Otterson, G.A., Patel, S.H., Sugawara, S., Naidoo, J., Multisystem Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer, JAMA Oncology, 6, (12), 2020, p1952-1956
Friedes, C., Mai, N., Fu, W., Hu, C., Hazell, S.Z., Han, P., McNutt, T.R., Forde, P.M., Redmond, K.J., Voong, K.R., Hales, R.K., Isolated progression of metastatic lung cancer: Clinical outcomes associated with definitive radiotherapy, Cancer, 126, (20), 2020, p4572-4583
Lam, V.K., Forde, P.M., Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer, Journal of Thoracic Oncology, 15, (10), 2020, p1556-1558
Naidoo, J., Cottrell, T.R., Lipson, E.J., Forde, P.M., Illei, P.B., Yarmus, L.B., Voong, K.R., Feller-Kopman, D., Lee, H., Riemer, J., Wang, D., Taube, J.M., Brahmer, J.R., Lin, C.T., Danoff, S.K., D'Alessio, F.R., Suresh, K., Chronic immune checkpoint inhibitor pneumonitis, Journal for ImmunoTherapy of Cancer, 8, (1), 2020
Reuss, J.E., Forde, P.M., Immunotherapy for mesothelioma: Rationale and new approaches, Clinical Advances in Hematology and Oncology, 18, (9), 2020, p562-572
Reuss, J.E., Anagnostou, V., Cottrell, T.R., Smith, K.N., Verde, F., Zahurak, M., Lanis, M., Murray, J.C., Chan, H.Y., McCarthy, C., Wang, D., White, J.R., Yang, S., Battafarano, R., Broderick, S., Bush, E., Brock, M., Ha, J., Jones, D., Merghoub, T., Taube, J., Velculescu, V.E., Rosner, G., Illei, P., Pardoll, D.M., Topalian, S., Naidoo, J., Levy, B., Hellmann, M.D., Brahmer, J.R., Chaft, J.E., Forde, P.M., Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer, Journal for ImmunoTherapy of Cancer, 8, (2), 2020
Forde, P.M., Scherpereel, A., Tsao, A.S., Use of Immune Checkpoint Inhibitors in Mesothelioma, Current Treatment Options in Oncology, 20, (2), 2019
Danilova, L., Anagnostou, V., Caushi, J.X., Sidhom, J.-W., Guo, H., Chan, H.Y., Suri, P., Tam, A., Zhang, J., Asmar, M.E., Marrone, K.A., Naidoo, J., Brahmer, J.R., Forde, P.M., Baras, A.S., Cope, L., Velculescu, V.E., Pardoll, D.M., Housseau, F., Smith, K.N., The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: A sensitive platform for monitoring antitumor immunity, Cancer Immunology Research, 6, (8), 2018, p888-899
Marrone, K.A., Zhou, X., Forde, P.M., Purtell, M., Brahmer, J.R., Hann, C.L., Kelly, R.J., Coleman, B., Gabrielson, E., Rosner, G.L., Ettinger, D.S., A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer, Oncologist, 23, (7), 2018, p859-865
Marrone, K.A., Forde, P.M., Cancer immunotherapy in older patients, Cancer Journal (United States), 23, (4), 2017, p219-222
Baik, C.S., Rubin, E.H., Forde, P.M., Mehnert, J.M., Collyar, D., Butler, M.O., Dixon, E.L., Chow, L.Q.M., Immuno-oncology clinical trial design: Limitations, challenges, and opportunities, Clinical Cancer Research, 23, (17), 2017, p4992-5002
Naidoo, J., Cappelli, L.C., Forde, P.M., Marrone, K.A., Lipson, E.J., Hammers, H.J., Sharfman, W.H., Le, D.T., Baer, A.N., Shah, A.A., Albayda, J., Manno, R.L., Haque, U., Gutierrez, A.K., Bingham, C.O., Brahmer, J.R., Inflammatory arthritis: A newly recognized adverse event of immune checkpoint blockade, Oncologist, 22, (6), 2017, p627-630
Anagnostou, V., Yarchoan, M., Hansen, A.R., Wang, H., Verde, F., Sharon, E., Collyar, D., Chow, L.Q.M., Forde, P.M., Immuno-oncology trial endpoints: Capturing clinically meaningful activity, Clinical Cancer Research, 23, (17), 2017, p4959-4969
Illei, P.B., Belchis, D., Tseng, L.-H., Nguyen, D., De Marchi, F., Haley, L., Riel, S., Beierl, K., Zheng, G., Brahmer, J.R., Askin, F.B., Gocke, C.D., Eshleman, J.R., Forde, P.M., Lin, M.-T., Clinical mutational profiling of 1006 lung cancers by next generation sequencing, Oncotarget, 8, (57), 2017, p96684-96696
Anagnostou, V., Smith, K.N., Forde, P.M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., Hruban, C., Guthrie, V.B., Rodgers, K., Naidoo, J., Kang, H., Sharfman, W., Georgiades, C., Verde, F., Illei, P., Li, Q.K., Gabrielson, E., Brock, M.V., Zahnow, C.A., Baylin, S.B., Scharpf, R.B., Brahmer, J.R., Karchin, R., Pardoll, D.M., Velculescu, V.E., Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer, Cancer Discovery, 7, (3), 2017, p264-276
Zeidan, A., Faltas, B., Forde, P., Subhawong, A., Bello, C., Bolaños-Meade, J., Sequential occurrence of a splenic marginal zone lymphoma, extranodal MALT lymphoma, and hodgkin lymphoma, Clinical Lymphoma, Myeloma and Leukemia, 13, (4), 2013, p496-498
Zeidan, A.M., Forde, P.M., Streiff, M.B., Diagnosis, Treatment, and Prevention of Cancer-Associated Venous Thromboembolism, Abeloff's Clinical Oncology: Fifth Edition, 2013, p542-561
Forde, P.M., Ettinger, D.S., Targeted therapy for non-small-cell lung cancer: Past, present and future, Expert Review of Anticancer Therapy, 13, (6), 2013, p745-758
Boikos, S.A., Forde, P.M., Chatterjee, S., Hann, C.L., Tumor lysis syndrome in limited-stage small-cell lung cancer, Journal of Thoracic Oncology, 8, (7), 2013
Forde, P.M., Kelly, R.J., Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies, Oncologist, 18, (7), 2013, p823-832
Forde, P.M., Reiss, K.A., Zeidan, A.M., Brahmer, J.R., What lies within: Novel strategies in immunotherapy for non-small cell lung cancer, Oncologist, 18, (11), 2013, p1203-1213
Forde, P.M., Kelly, R.J., Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer, Journal of Thoracic Oncology, 8, (6), 2013, p673-684
Forde, PM, Rock, K, Wilson, G, O'Byrne, KJ, Ipilimumab-induced Immune-related Renal Failure - A Case Report, ANTICANCER RESEARCH, 32, (10), 2012, p4607-4608
Forde, P.M., Rudin, C.M., Crizotinib in the treatment of non-small-cell lung cancer, Expert Opinion on Pharmacotherapy, 13, (8), 2012, p1195-1201
Lefter, S., Forde, P., Nashat, H., Moylan, E., Yacoob, Y., A 27-year-old man with diplopia, fatiguable ptosis and rash: A rare presentation of angiocentric T cell lymphoma with lymphomatoid vasculitis, BMJ Case Reports, 2011
Forde, P., Murphy, C., O'Sullivan, C., Carney, D., Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer, Irish Journal of Medical Science, 180, (1), 2011, p283-284
Rock, C., Brady, D., Forde, P., Lucey, P., Horgan, M., Leptospirosis: a globally increasing zoonotic disease., BMJ case reports, 2010, 2010
Recognition
Awards and Honours
ECOG-ACRIN Young Investigator Award
Daniel C. Ihde Award for Medical Oncology, International Association for the Study of Lung Cancer
Memberships
Member of European Society of Medical Oncology, American Association for Cancer Research, American Society of Clinical Oncology